Across TCGA pan-cancer cohorts, TRAJ14 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated TRAJ14 data layer compared with 13 for mass-spec protein.
The strongest signal is observed in esophageal carcinoma (ESCA), where higher TRAJ14 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAJ14 expression acts as an unfavorable survival marker.
ESCA are the cancer types where TRAJ14 Mutation most reproducibly stratifies survival.